Cost-effectiveness of antibody-drug conjugates in previously treated metastatic triple-negative breast cancer in China
Shixian Liu, Kaixuan Wang, Ruixue Wang, Hao Chen, Ziming Wan, Lei Dou, Shunping Li · 2025
Read Cost-effectiveness of antibody-drug conjugates in previously treated metastatic triple-negative breast cancer in China by Shixian Liu, Kaixuan Wang, Ruixue Wang, Hao Chen, Ziming Wan, Lei Dou, Shunping Li (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12750699.txt.
Description
Shixian Liu and co-authors price two guided-missile cancer drugs for Chinese care in a 2025 study. Antibody-drug conjugates ferry poison straight to tumor cells, and two of them, similar in name and target, beat chemotherapy in trials for metastatic triple-negative breast cancer that had already been treated. Whether their benefit justifies their price, from China's healthcare system's view, was the question.
A survival model simulated costs and quality-adjusted life-years over ten years, against a willingness-to-pay line near forty thousand dollars per quality year. One drug, sacituzumab tirumotecan, landed closer to the line and flatly dominated its sibling: cheaper and more effective. The other, sacituzumab govitecan, cost several times the threshold per quality year. Both verdicts hinged on unit price, and the paper names the price cuts that would flip each result.
Catalog record
| CREATOR | Shixian Liu, Kaixuan Wang, Ruixue Wang, Hao Chen, Ziming Wan, Lei Dou, Shunping Li |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |